Akari Therapeutics plc has received a notification from Nasdaq indicating that the company is not in compliance with the minimum bid price requirement, which mandates a closing bid price of at least $1.00 per share. The company has 180 calendar days, until May 25, 2026, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. If Akari does not meet this requirement by the deadline, it may be eligible for an additional 180-day compliance period if certain conditions are met. Failure to regain compliance could result in the delisting of its American Depositary Shares from the Nasdaq Capital Market, though the company would have the opportunity to appeal any delisting decision.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-25-025177), on November 26, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.